+44-1518-0811362025: Volume 9, Issue 3
Editorial P.1-2
Personalized Antiviral Therapy: Tailoring Treatment to Viral Genotype and Host Response
Author(s):
Inaya Naya
DOI: 10.35841/AAVRJ-9.3.201
Editorial P.1-2
Targeting Viral Entry: Novel Inhibitors of Host-Pathogen Interactions
Author(s):
Muhammad Waqar Mazhar
DOI: 10.35841/AAVRJ-9.3.202
Editorial P.1-2
Cancerâ??s Counterattack: Drug Resistance in Oncology Treatments
Author(s):
Wan Jing
DOI: 10.35841/AAVRJ-9.3.203
Editorial P.1-2
Synthetic Biology Approaches to Antiviral Drug Design
Author(s):
Cesaire Awando
DOI: 10.35841/AAVRJ-9.3.204
Editorial P.1-2
Real-Time Monitoring of Antiviral Efficacy Using Biosensors
Author(s):
Kasturi Vena
DOI: 10.35841/AAVRJ-9.3.205
Editorial P.1-2
Machine Learning in Antiviral Drug Discovery: Accelerating Innovation
Author(s):
Ualiveya Thuluva
DOI: 10.35841/AAVRJ-9.3.206
Editorial P.1-2
Antiviral Peptides: Natural Defenses Reimagined for Clinical Use
Author(s):
Dina Mofed
DOI: 10.35841/AAVRJ-9.3.207
Editorial P.1-2
Small Molecule Inhibitors of Viral Polymerases: A New Era in Antiviral Design
Author(s):
Litao (Lee) Zheng
DOI: 10.35841/AAVRJ-9.3.208
Editorial P.1-2
Direct-Acting Antivirals: Revolutionizing SVR Rates in HCV
Author(s):
Qiang Fang
DOI: 10.35841/AAVRJ-9.3.209
Editorial P.1-2
From Infection to Cure: How SVR Transforms Patient Outcomes
Author(s):
Yuze Haoran
DOI: 10.35841/AAVRJ-9.3.210